News | January 15, 2015

Society of Interventional Radiology Launches New Brand Reinforcing Commitment to Develop New Treatments

New branding designed to enhance medical practice and improve standard of patient care through image-guided therapies

January 15, 2015 — The Society of Interventional Radiology (SIR) unveiled a new brand for the society and its research organization, the SIR Foundation. The new logos for both organizations convey the limitless possibilities of image-guided therapies to solve the toughest medical problems. SIR’s new tagline, “The vision to heal,” reflects the innovative, patient-driven care that board-certified interventional radiologists deliver through methods that result in less risk, less pain and shorter recovery time than traditional surgery.

“Interventional radiology showcases the very best of today’s medicine, bringing together clinical insight, procedural expertise and advanced image-guided technology to deliver high-quality patient care,” said SIR President James B. Spies, M.D., MPH, FSIR. “Our efforts reinforce how SIR continues to support our members as they deliver outstanding clinical care and how we will continue to do so in the years to come,” added Spies.

With the renewed focus on cost-effective, patient-driven care in the evolving healthcare landscape, SIR and SIR Foundation actively reaffirm interventional radiology’s role as part of the greater care team. Through the new brand, the society strengthens its identity, promoting the value that interventional radiology delivers — the same value being called for in medicine: better outcomes, less burden on the patient and innovative use of technology with clear patient benefit, noted Spies.

“Our new brand helps us to better communicate the valuable and unique role that interventional radiology has in delivering comprehensive clinical care,” said SIR Executive Director Susan E. Sedory Holzer, M.A., CAE. “By listening to our members, this new framework also reflects the passion and dedication members have for the specialty and, more importantly, high-quality care,” added Holzer.

For more information: www.sirweb.org

Related Content

Teleflex Launches Next-Generation Sympro Elite and Expro Elite Snares
Technology | Cath Lab | February 07, 2018
Teleflex Inc. has announced 510(k) clearance by the U.S. Food and Drug Administration (FDA) and U.S. commercial launch...
SCAI Advocacy Committee Highlights Reimbursement Reform Efforts in 2017
News | Cath Lab | January 30, 2018
The Society for Cardiovascular Angiography and Interventions (SCAI) highlighted the efforts of its Advocacy Committee...
IAC Releases Cardiovascular Catheterization Accreditation Program
News | Cath Lab | January 25, 2018
January 25, 2018 – The Intersocietal Accreditation Commission (IAC) announced the release of its Cardiovascular Cathe
Videos | Cath Lab | January 04, 2018
Bernadette Speiser, BSN, MSN, CCRN, RCIS, a cardiac cath/EP nurse at Palo Alto Veterans Hospital, Palo Alto, Calif.,
FDA Initiates Class I Recall of Sterilmed Reprocessed Agilis Steerable Introducer Sheath
News | Cath Lab | January 04, 2018
The U.S. Food and Drug Administration (FDA) announced a Class I recall of Sterilmed’s Agilis Steerable Introducer...
The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA atherectomy system. Athar Ansari, M.D.

The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA system. 

Feature | Cath Lab | November 24, 2017 | Athar Ansari, M.D., FACC
As debates about the current state and future of healthcare rage in Congress, the media and healthcare settings acros
Videos | Cath Lab | November 08, 2017
Juan Granada, M.D., Cardiovascular Research Foundation president and chief executive officer, shares his insights on
Results of the ORBITA study found no difference in exercise time after six weeks in patients with stable angina who received percutaneous coronary intervention (PCI) versus a placebo treatment. TCT 2017
Feature | Cath Lab | November 06, 2017
November 6, 2017 – Results from ORBITA, a prospective multi-center randomized blinded placebo-controlled study, found
Culprit Lesion-Only PCI Improves Outcomes for Cardiogenic Shock Patients Compared to Multivessel PCI
News | Cath Lab | November 01, 2017
November 1, 2017 — Results from the prospective, randomized, multicenter CULPRIT-SHOCK trial found an initial strateg
Overlay Init